Loading clinical trials...
Loading clinical trials...
Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 ® Inhalation in Patients With Moderate COVID-19 Who Did Not Require Treatment in the Intensive Care Unit.
Conditions
Interventions
MIR 19 ®
Standard COVID-19 therapy
Locations
1
Russia
NRC Institute of Immunology FMBA
Moscow, Russia
Start Date
April 27, 2021
Primary Completion Date
September 7, 2021
Completion Date
September 7, 2021
Last Updated
January 11, 2022
NCT06082518
NCT07221162
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions